<embed src="http://v.ku6vms.com/phpvms/player/html/vid/U8HV94PyuhAre5xy/style/m1hYLVJ_Ax8./" quality="high" width="260" height="260" align="middle" allowScriptAccess="always" allowfullscreen="true" type="application/x-shockwave-flash"></embed>
GLP-1综合资讯
- 10-05-122 型糖尿病的病程进展及其特点
- 10-05-12利拉鲁肽 一天一次的人GLP- 1 类似物
- 10-05-12肝门静脉内GLP-1受体与人体进食调节无关
- 10-05-12综述：各种GLP-1受体激动剂及DPP-4抑制剂的有效性及安全性
- 10-05-12综述：各种GLP-1受体激动剂及DPP-4抑制剂的结构、作用机制及药理学
- 10-05-12Defining and characterising the progression of ...
- 10-05-12Liraglutide a once-daily human GLP-1 analogue
- 10-05-12Pharmacology of GLP-1-based therapies
- 10-05-11Glucagon-like peptide-1 receptor agonists in t ...
- 10-05-11诺和诺德公司新药Victoza® （利拉鲁肽）获欧盟管理当局积极评价
- 10-05-11Liraglutide(利拉鲁肽)安全性、有效性3期临床研究LEAD的6 ...
- 10-05-11胰岛素抵抗是冠脉病变进展的独立预测因子
- 10-05-06抗击糖尿病 减少低血糖并发症危害--GLP-1葡萄糖浓度依赖性降糖显优势
- 10-05-062型糖尿病患者使用新一代GLP-1制剂Liraglutide的研究
- 10-05-06Glucagon-Like Peptide-1 Inhibits Blood-Bra ...
- 10-05-06Medscape与Peerview联手奉献GLP-1最新资讯